


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. – 26. (Canceled)

27. (New) A compound of the formula I:



in which:

R^1, R^2 are each, independently of one another, H, OH, OR^8 , $-SR^8$, $-SOR^8$, $-SO_2R^8$ or Hal, or


R^1 and R^2 together are alternatively $-OCH_2O-$ or $-OCH_2CH_2O-$;

R^3 is H, $A''R^7$, $COA''R^7$, $COOA''R^7$, $CONH_2$, $CONHA''R^7$, $CON(A''R^7)(A'''R^7)$, $CONR^{10}Het$, NH_2 , $NHA''R^7$, $N(A''R^7)(A'''R^7)$, $NCOA''R^7$ or $NCOOA''R^7$;

B is an aromatic isocyclic or heterocyclic radical, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by R^4 , R^5 and/or R^6 ;

X is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH_2 groups are optionally replaced by O, S, SO, SO_2 , NH or $NA''R^7$, and 1-7 H atoms are optionally replaced by F and/or Cl;

R^4, R^5, R^6 are each, independently of one another, H, $A''R^7$, OH, $OA''R^7$, NO_2 , NH_2 , $NHA''R^7$, $N(A''R^7)(A'''R^7)$, $NHCOA''R^7$, $NHCOOA''R^7$, $NHCONH_2$, $NHCONHA''R^7$, $NHCON(A''R^7)(A'''R^7)$, Hal, COOH, $COOA''R^7$, $CONH_2$, $CONHA''R^7$, $CON(A''R^7)(A'''R^7)$,



R^7 is H, COOH, COOA, CONH₂, CONHA, CONAA', NH₂, NHA, NAA', NCOA, NCOOA, OH or OA;

R^8 is A, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms;

R^9 is alkyl having 1-10 carbon atoms, cycloalkyl having 3-7 carbon atoms, alkylenecycloalkyl having 4-8 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH, NMe, NEt and/or by -CH=CH- groups, 1-7 H atoms are optionally replaced by F and/or Cl, and/or 1 H atom is optionally replaced by R^7 ,

Y is alkylene having 1-10 carbon atoms or alkenylene having 2-8 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH or NR⁹ and/or 1-7 H atoms are optionally replaced by F and/or Cl;

A, A' are each, independently of one another, aryl, Het, alkyl having 1-10 carbon atoms or alkenyl having 2-8 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH or NR⁹ and/or 1-7 H atoms may be replaced by F and/or Cl, or

A and A' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH, NR⁹, NCOR⁹ or NCOOR⁹;

A'', A''' are each, independently of one another, a single bond, alkylene having 1-10 carbon atoms, alkenylene having 2-8 carbon atoms or cycloalkylene having 3-7 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH or NR⁹ and/or 1-7 H atoms are optionally replaced by F and/or Cl, or

A'' and A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one, two or three CH₂ groups are optionally replaced by O, S, SO, SO₂, NH, NR⁹, NCOR⁹ or NCOOR⁹;

aryl is phenyl, naphthyl, fluorenyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, R¹¹, OR¹⁰, N(R¹⁰)₂, NO₂, CN, COOR¹⁰, CON(R¹⁰)₂, NR¹⁰COR¹⁰, NR¹⁰CON(R¹⁰)₂, NR¹⁰SO₂A, COR¹⁰, SO₂N(R¹⁰)₂, or S(O)_mR¹¹;

R¹⁰ is H or alkyl having 1-6 carbon atoms,

R¹¹ is alkyl having 1-6 carbon atoms,

Het is a monocyclic or bicyclic saturated, unsaturated or aromatic heterocyclic ring having 1 to 2 N, O and/or S atoms, which is unsubstituted or monosubstituted or disubstituted by carbonyl oxygen, Hal, R¹¹, OR¹⁰, N(R¹⁰)₂, NO₂, CN, COOR¹⁰, CON(R¹⁰)₂, NR¹⁰COR¹⁰, NR¹⁰CON(R¹⁰)₂, NR¹⁰SO₂R¹¹, COR¹⁰, SO₂NR¹⁰ and/or S(O)_mR¹¹,

Hal is F, Cl, Br or I, and

m is 0, 1 or 2,

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,

or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,

or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

28. (New) A compound according to Claim 27, in which

R¹, R² are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms,

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,

or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,

or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

29. (New) A compound according to Claim 27, in which
 R^1, R^2 are each, independently of one another, H, methoxy, ethoxy, benzyloxy, propoxy, isopropoxy, difluoromethoxy, F, Cl, cyclopentyloxy, cyclohexyloxy or cycloheptyloxy,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

30. (New) A compound according to Claim 27, in which
 R^1, R^2 are each, independently of one another, methoxy, ethoxy, propoxy, isopropoxy, cyclopentyloxy or F,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

31. (New) A compound according to Claim 27, in which
 R^1 is 4-methoxy,
 R^2 is 3-ethoxy or 3-propoxy,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.


32. (New) A compound according to Claim 27, in which
 R^3 is H, $A''R^7$, $COA''R^7$, $CON(A''R^7)(A'''R^7)$ or $CO-NR^{10}$ -Het,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,

or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

33. (New) A compound according to Claim 27, in which
X is methylene, ethylene, propylene or butylene,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.


34. (New) A compound according to Claim 27, in which
B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by R⁴, R⁵ and/or R⁶,
or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

35. (New) A compound according to Claim 27, in which
B is phenyl, pyridyl, pyridyl N-oxide, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, isoxazolinyl, oxazolinyl, thiazolinyl, pyrazolinyl, imidazolinyl, naphthyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl or quinoxalinyl, each of which is unsubstituted or may be monosubstituted, disubstituted or trisubstituted by OH, OA, NO₂, NH₂, NAA',



or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
 or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
 or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or
 E/Z isomers in all ratios.


- 36. (New)** A compound according to Claim 27, in which
 B is phenyl which is unsubstituted or monosubstituted by OR¹⁰, NO₂ or



or unsubstituted pyridyl or pyridyl N-oxide,
 or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
 or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
 or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or
 E/Z isomers in all ratios.

- 37. (New)** A compound according to Claim 27, in which
 R¹, R² are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon
 atoms,
 X is methylene, ethylene, propylene or butylene,

- R^3 is H, $A''R^7$, $COA''R^7$, $CON(A''R^7)(A'''R^7)$ or $CO-NR^{10}$ -Het,
 A'' , A''' are each, independently of one another, a single bond, or alkylene having 1-10 carbon atoms, in which one CH_2 group is optionally replaced by NH or NR^9 , or
 A'' , A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH_2 group is optionally replaced by NH or NR^9 ,
 B is phenyl which is unsubstituted or monosubstituted by OR^{10} , NO_2 ,




- NH_2 or $NHCOOA''R^7$, or unsubstituted pyridyl or pyridyl N-oxide,
 R^7 is H, $COOH$, NHA or NAA' ,
 R^9 is alkyl having 1-6 carbon atoms,
 R^{10} is H or alkyl having 1-6 carbon atoms,
 A , A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F and/or Cl,
Het is a monocyclic saturated heterocyclic radical having 1 to 2 N atoms, which is optionally monosubstituted or disubstituted by alkyl having 1-6 carbon atoms, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

38. (New) A compound according to Claim 27, in which

- R^1 , R^2 are each, independently of one another, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms,
 X is methylene, ethylene, propylene or butylene,
 R^3 is H, $A''R^7$, $COA''R^7$, $CON(A''R^7)(A'''R^7)$ or $CO-NR^{10}$ -Het,
 A'' , A''' are each, independently of one another, a single bond or alkylene having 1-10 carbon atoms, in which one CH_2 group is optionally replaced by NH or NR^9 , or

A", A''' together are alternatively an alkylene chain having 2-7 carbon atoms, in which one CH₂ group is optionally replaced by NH or NR⁹,

B is phenyl which is unsubstituted or monosubstituted by OR¹⁰, NO₂,



NH₂ or NHCOOA"R⁷, or unsubstituted pyridyl or pyridyl N-oxide,

R⁷ is H, COOH, NHA or NAA',

R⁹ is alkyl having 1-6 carbon atoms,

R¹⁰ is H or alkyl having 1-6 carbon atoms,

A, A' are each, independently of one another, alkyl having 1-10 carbon atoms, in which 1-7 H atoms may be replaced by F and/or Cl,

Het is a monocyclic saturated heterocyclic radical having 1 to 2 N atoms, which is optionally monosubstituted or disubstituted by alkyl having 1-6 carbon atoms, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios.

39. (New) A compound according to Claim 27, selected from the group consisting of :


- 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- benzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- 4-hydroxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- pyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,

- e) 1-oxypyridine-4-carbaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- f) 4-methoxybenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- g) benzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- h) pyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- i) 1-oxypyridine-4-carbaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- j) 4-nitrobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- k) 4-aminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- l) 4-tert-butyloxycarbonylaminobenzaldehyde O-{2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- m) 2-{[4-(2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino)methyl]phenyl]hydrazono} malononitrile,
- n) 2-{[3-(2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino)methyl]phenyl]hydrazono} malononitrile,
- o) 2-{[4-(2-[3-(4-methoxy-3-propoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino)methyl]phenyl]hydrazono} malononitrile,
- p) {2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino}-2-phenylacetic acid,
- q) 2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino}-N-methyl-N-(1-methylpiperidin-4-yl)-2-phenylacetamide,
- r) 1-(4-methylpiperazin-1-yl)-2-phenylethane-1,2-dione 2-(O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl} oxime,
- s) N-(2-dimethylaminoethyl)-2-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino}-2-phenylacetamide, and
- t) 2-{[4-(2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethoxyimino)methyl]phenyl]hydrazono}-2-(1H-tetrazol-5-yl)acetonitrile,


or a pharmaceutically acceptable salt, hydrate, or solvate thereof,
 or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups,
 or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or
 E/Z isomers in all ratios.

40. (New) A process for making a compound of Claim 27, which comprises:

a) reacting a compound of the formula II




in which X, R¹ and R² are as defined in Claim 27,
 with a compound of the formula III




in which R³ and B are as defined in Claim 27,
 wherein optionally any further OH and/or amino group present is protected by a protecting
 group and, optionally, the protecting group is subsequently removed,
 or

b) reacting a compound of the formula IV



in which R¹ and R² are as defined in Claim 27,

with a compound of the formula V




in which L is Cl, Br, I or a free or reactively functionally modified OH group,

and R^3 , X and B are as defined in Claim 27,

wherein optionally any further OH and/or amino group present is protected by a protecting group and, optionally, the protecting group is subsequently removed,


or

c) reacting a compound of the formula VI



in which X, R^1 and R^2 are as defined in Claim 27, and L is Cl, Br, I or a free or reactively functionally modified OH group,

with a compound of the formula VII



in which R^3 and B are as defined in Claim 27,

wherein optionally any further OH and/or amino group present is protected by a protecting group and, optionally, the protecting group is subsequently removed,

or

- d) converting one or more radicals R^1 , R^2 , R^3 and/or B in a compound of the formula I into one or more other radicals R^1 , R^2 , R^3 and/or B by
- i) cleaving an ether or ester,
 - ii) alkylating or acylating an OH function,
 - iii) reductively alkylating an amino group,
 - iv) reacting an amino group with malononitrile,
 - v) converting a cyano group into a tetrazole group,

and, optionally, converting a basic compound of the formula I into a salt thereof by treatment with an acid.

41. (New) A pharmaceutical composition comprising at least one compound of the formula I according to claim 27 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios and a pharmaceutically acceptable excipient.

42. (New) A method of preparing a pharmaceutical composition for the treatment of a patient suffering from a disease or condition mediated by the PDE IV isozyme in its role in regulating the activation and degranulation of human eosinophils, which comprises combining at least one compound of the formula I according to claim 27 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios with a pharmaceutically acceptable excipient.

43. (New) A method of preparing a pharmaceutical composition for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, autoimmune diseases, rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus, ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumour growth or tumour metastases, sepsis, memory disorders, atherosclerosis and/or AIDS which comprises combining at least one compound

of the formula I according to claim 27 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios with a pharmaceutically acceptable excipient.

44. (New) A method comprising administering to a patient in need thereof a composition according to claim 41 to treat: asthma; chronic or acute bronchoconstriction; bronchitis; small airway obstruction and emphysema; an obstructive or inflammatory airway disease; pneumoconiosis; bronchiectasis; rhinitis; sinusitis; rheumatoid arthritis; gout; fever or pain associated with inflammation; an eosinophil-related pathological disorder; dermatitis; eczema; urticaria; conjunctivitis; uveitis; psoriasis; multiple sclerosis; an autoimmune/inflammatory disease; foreign transplant rejection following organ transplantation; inflammatory bowel disease; septic shock; liver damage; pulmonary hypertension and hypoxia-induced pulmonary hypertension; bone loss diseases; osteoporosis; pathological disorders of the central nervous system; infections; ischaemia-reperfusion damage; autoimmune diabetes; retinal autoimmunity; chronic lymphocytic leukaemia; HIV infections; lupus erythematosus; kidney and ureter diseases; pathological urogenital and gastrointestinal disorders and prostate diseases.

45. (New) A method comprising administering to a patient in need thereof a composition according to claim 41 to treat: (1) an inflammatory disease or condition, selected from joint inflammation, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, inflammatory bowel disease, ulcerative colitis, chronic glomerulonephritis, dermatitis and Crohn's disease; (2) an airway disease or condition, selected from asthma, acute respiratory distress syndrome, chronic pulmonary inflammatory disease, bronchitis, chronic obstructive airway disease and silicosis; (3) an infectious disease or condition, selected from sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, fever and myalgia due to bacterial, viral or fungal infections, and influenza; (4) an immune disease or condition selected from autoimmune diabetes, systemic lupus erythematosus, GvH reaction, rejection of foreign transplants, multiple sclerosis, psoriasis and allergic rhinitis; or (5) another disease or condition selected from bone absorption diseases, reperfusion damage, cachexia secondary to infection or malignancy, cachexia

secondary to AIDS, human immunodeficiency virus (HIV) infection, or AIDS related complex (ARC), keloid formation, scar tissue formation, type 1 diabetes mellitus, and leukaemia.

46. (New) A method comprising administering to a patient in need thereof a composition according to claim 41 to treat a myocardial disease.

47. (New) A method according to Claim 46, wherein the myocardial disease has inflammatory and immunological properties.

48. (New) A method comprising administering to a patient in need thereof a composition according to claim 41 to treat coronary heart disease, reversible or irreversible myocardial ischaemia/reperfusion damage, acute or chronic heart failure, or restenosis.

49. (New) A composition according to Claim 41, further comprising at least one of:

- (a) a leukotriene biosynthesis inhibitor;
- (b) a receptor antagonist for the leukotrienes LTB₄, LTC₄, LTD₄ and LTE₄;
- (c) a PDE IV inhibitor;
- (d) a 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist;
- (e) a dual inhibitor of 5-lipoxygenase (5-LO) and antagonist of platelet activating factor (PAF);
- (f) a leukotriene antagonist;
- (g) an antihistamine H₁ receptor antagonist;
- (h) a gastroprotective H₂ receptor antagonist;
- (i) an α_1 - and α_2 -adrenoreceptor agonist vasoconstrictor sympathomimetic agent;
- (k) an anticholinergic agent;
- (l) an α_1 - to α_4 -adrenoreceptor agonist;
- (m) theophylline or aminophylline;
- (n) sodium cromoglycate;

- (o) a muscarinic receptor (M1, M2 and M3) antagonist;
- (p) a COX-1 inhibitor or nitric oxide;
- (q) the COX-2 selective inhibitor rofecoxib;
- (r) an insulin-like growth factor type I (IGF-1) mimetic;
- (s) ciclesonide;
- (t) an inhalation glucocorticoid with reduced systemic side effects;
- (u) a tryptase inhibitor;
- (v) a platelet activating factor (PAF) antagonist;
- (w) a monoclonal antibody against endogenous inflammatory entities;
- (y) an antitumour necrosis factor agent;
- (z) leflunomide;
- (aa) a TCR peptide;
- (bb) an interleukin converting enzyme (ICE) inhibitor;
- (cc) an IMPDH inhibitor;
- (dd) an adhesion molecule inhibitor;
- (ee) a cathepsin;
- (ff) a MAP kinase inhibitor;
- (gg) a glucose 6-phosphate dehydrogenase inhibitor;
- (hh) a kinin B₁ and B₂ receptor antagonist;
- (ii) gold in the form of an aurothio group together with hydrophilic groups;
- (jj) an immunosuppressive agent selected from the group consisting of cyclosporine, azathioprine and methotrexate;
- (kk) an anti-gout agent selected from the group consisting of colchicines;
- (ll) allopurinol;
- (mm) probenecide, sulfinpyrazone or benzbromarone;
- (nn) vinblastine or vincristine;
- (oo) an agent for promoting growth hormone secretion;
- (pp) an inhibitor of matrix metalloproteases (MMPs) selected from the group consisting of stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11);
- (qq) transforming growth factor (TGF β);

- (rr) platelet-derived growth factor (PDGF);
- (ss) basic fibroblast growth factor (bFGF);
- (tt) granulocyte macrophage colony stimulating factor (GM-CSF);
- (uu) capsaicin;
- (vv) a tachykinin NK₁ and NK₃ receptor antagonist;
- (ww) an elastase inhibitor;
- and
- (xx) an adenosine A_{2a} receptor agonist.

50. (New) A kit comprising separate packs of:

- (a) a pharmaceutically effective amount of at least one compound of the formula I according to claim 27 or a pharmaceutically acceptable salt, hydrate, or solvate thereof, or a derivative thereof modified by alkyl, acyl, sugar or oligopeptide groups, or an isolated stereoisomer or E/Z isomer thereof or mixtures of such stereoisomers or E/Z isomers in all ratios,
- and
- (b) a pharmaceutically effective amount of a different pharmaceutically active ingredient.

51. (New) A kit according to Claim 50, wherein the different pharmaceutically active ingredient comprises at least one of:

- (a) a leukotriene biosynthesis inhibitor;
- (b) a receptor antagonist for the leukotrienes LTB₄, LTC₄, LTD₄ and LTE₄;
- (c) a PDE IV inhibitor;
- (d) a 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist;
- (e) a dual inhibitor of 5-lipoxygenase (5-LO) and antagonist of platelet activating factor (PAF);
- (f) a leukotriene antagonist;
- (g) an antihistamine H₁ receptor antagonist;
- (h) a gastroprotective H₂ receptor antagonist;
- (i) an α_1 - and α_2 -adrenoreceptor agonist vasoconstrictor sympathomimetic agent;

- (k) an anticholinergic agent;
- (l) an α_1 - to α_4 -adrenoreceptor agonist;
- (m) theophylline or aminophylline;
- (n) sodium cromoglycate;
- (o) a muscarinic receptor (M1, M2 and M3) antagonist;
- (p) a COX-1 inhibitor or nitric oxide;
- (q) the COX-2 selective inhibitor rofecoxib;
- (r) an insulin-like growth factor type I (IGF-1) mimetic;
- (s) ciclesonide;
- (t) an inhalation glucocorticoid with reduced systemic side effects;
- (u) a tryptase inhibitor;
- (v) a platelet activating factor (PAF) antagonist;
- (w) a monoclonal antibody against endogenous inflammatory entities;
- (y) an antitumour necrosis factor agent;
- (z) leflunomide;
- (aa) a TCR peptide;
- (bb) an interleukin converting enzyme (ICE) inhibitor;
- (cc) an IMPDH inhibitor;
- (dd) an adhesion molecule inhibitor;
- (ee) a cathepsin;
- (ff) a MAP kinase inhibitor;
- (gg) a glucose 6-phosphate dehydrogenase inhibitor;
- (hh) a kinin B₁ and B₂ receptor antagonist;
- (ii) gold in the form of an aurothio group together with hydrophilic groups;
- (jj) an immunosuppressive agent selected from the group consisting of cyclosporine, azathioprine and methotrexate;
- (kk) an anti-gout agent selected from the group consisting of colchicines;
- (ll) allopurinol;
- (mm) probenecide, sulfinpyrazone or benzbromarone;
- (nn) vinblastine or vincristine;
- (oo) an agent for promoting growth hormone secretion;

- (pp) an inhibitor of matrix metalloproteases (MMPs) selected from the group consisting of stromelysins, collagenases, gelatinases, aggrecanase, collagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10) and stromelysin-3 (MMP-11);
- (qq) transforming growth factor (TGF β);
- (rr) platelet-derived growth factor (PDGF);
- (ss) basic fibroblast growth factor (bFGF);
- (tt) granulocyte macrophage colony stimulating factor (GM-CSF);
- (uu) capsaicin;
- (vv) a tachykinin NK₁ and NK₃ receptor antagonist;
- (ww) an elastase inhibitor;
- and
- (xx) an adenosine A2a receptor agonist.